Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported equity compensation activity involving restricted stock units and related common stock. On February 20 and 23, 2026, restricted stock units vested and were settled into a total of 22436 and 16757 shares of common stock through derivative exercises.
On both dates, a portion of the newly delivered common shares, 9040 and 12104 shares respectively, was automatically withheld by the issuer to cover tax withholding obligations at prices of $70.98 and $70.64 per share, rather than sold in open‑market transactions. After these transactions, Torley directly owned 767780 shares of common stock and 44872 restricted stock units.
Snyder Mark Howard reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 42,692 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 4,796 shares.
LaBrosse Nicole reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 60,440 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 5,329 shares.
Torley Helen reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 226,153 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 16,874 shares.
Halozyme Therapeutics, Inc. presents an annual overview of its business focused on drug-delivery technologies that convert intravenous therapies to subcutaneous injections. The company’s ENHANZE platform, based on its rHuPH20 enzyme, is widely licensed to major biopharma partners, generating upfront fees, milestones, bulk enzyme sales and royalties from ten commercial products.
Halozyme also develops Hypercon and Surf Bio hyperconcentration technologies and pressure-assisted auto-injectors, plus proprietary products Hylenex and XYOSTED. It highlights extensive global partnerships with Roche, Takeda, Janssen, argenx, BMS and others, alongside detailed risk factors spanning regulatory approval, supply chain, competition, financing, cybersecurity and market volatility.
Halozyme Therapeutics reported another year of strong top-line growth in 2025, with total revenue of $1.3966 billion, up 38% from 2024. Royalty revenue rose 52% to a record $867.8 million, driven mainly by ENHANZE-enabled products such as VYVGART Hytrulo, DARZALEX SC and Phesgo.
Despite this, full-year net income declined to $316.9 million from $444.1 million, as results absorbed $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition and higher operating costs. The company posted a fourth-quarter net loss of $141.6 million after these charges.
Halozyme expanded its drug-delivery portfolio by acquiring Elektrofi and Surf Bio and completed $1.5 billion of new convertible notes while increasing its revolving credit facility to $750 million. For 2026, it reiterates guidance for total revenue of $1.710–$1.810 billion, adjusted EBITDA of $1.125–$1.205 billion and non-GAAP diluted EPS of $7.75–$8.25, all implying robust double-digit growth over 2025.
Halozyme Therapeutics executive Cortney Caudill received new equity awards under the company’s compensation programs. On 02/09/2026, the SVP and Chief Operating Officer acquired an option to purchase 14,047 shares of common stock at $80.48 per share, vesting over four years starting 02/09/2027.
Caudill was also granted 13,047 restricted stock units that vest 25% on the first anniversary of the grant date and 25% on each anniversary thereafter. In addition, performance stock units tied to performance periods ending December 31, 2025 became eligible to vest, covering 2,403 and 14,751 shares, subject to continued service through the third anniversary of their original PSU grant dates.
Halozyme Therapeutics reported that SVP and Chief Legal Officer Mark Howard Snyder received several equity awards on February 9, 2026. He was granted an option to purchase 18,730 shares of common stock at an exercise price of $80.48, vesting one-fourth on the grant date and then monthly in equal installments.
He was also awarded 17,396 restricted stock units that vest in four equal annual installments starting one year after the grant, plus multiple performance stock unit awards. Performance stock units of 4,651, 7,808, and 29,502 shares became eligible to vest based on a performance period ending December 31, 2025 and remain subject to additional service-based vesting through the third anniversary of each original PSU grant date.
Halozyme Therapeutics executive Nicole LaBrosse, SVP and Chief Financial Officer, reported new equity awards tied to prior performance-based grants. On February 9, 2026, she acquired 5,167, 7,448, and 29,502 performance stock units at $0 per unit, each representing a contingent right to one share of common stock.
The units reflect the company’s determination of how many stock units became eligible to vest based on performance periods ending December 31, 2025 for PSU awards originally granted in 2023, 2024, and 2025. These awards remain subject to continued service through the third anniversary of each original grant date.
Halozyme Therapeutics President and CEO Helen Torley, who is also a director, reported receiving new equity awards on February 9, 2026. She was granted an option to purchase 53,847 shares of common stock at an exercise price of $80.48 per share.
Torley also acquired 50,013 restricted stock units, plus multiple performance stock unit (PSU) awards of 19,807, 24,985, and 92,714 units. These PSUs became eligible to vest based on a performance period ending December 31, 2025 and remain subject to ongoing service-based vesting, generally through the third anniversary of each PSU grant date.